[1]MERCHANT S. The JAK2 mutation[J/OL]. Int Rev Cell Mol Biol,2021,365:117-162[2022-10-30]. https://doi.org/10.1016/bs.ircmb.2021.09.002.
[2]PERNER F,PERNER C,ERNST T,et al. Roles of JAK2 in aging,inflammation,hematopoiesis and malignant transformation[J]. Cells,2019,8(8):854.
[3]GRINFELD J,NANGALIA J,BAXTER E J,et al. Classification and personalized prognosis in myeloproliferative neoplasms[J]. N Engl J Med,2018,379(15):1416-1430.
[4]ARELLANO-RODRIGO E,ALVAREZ-LARRÁN A,REVERTER J C,et al. Platelet turnover,coagulation factors,and soluble markers of platelet and endothelial activation in essential thrombocythemia:relationship with thrombosis occurrence and JAK2 V617F allele burden[J]. Am J Hematol,2009,84(2):102-108.
[5]HAUSCHNER H,BOKSTAD HOREV M,MISGAV M,et al. Platelets from calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets[J]. Am J Hematol,2020,95(4):379-386.
[6]HULTCRANTZ M,BJÖRKHOLM M,DICKMAN P W,et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms:a population-based cohort study[J]. Ann Intern Med,2018,168(5):317-325.
[7]POLIZIO A H,PARK E,WALSH K. Clonal hematopoiesis:connecting aging and inflammation in atherosclerosis[J]. Curr Atheroscler Rep,2023,25(3):105-111.
[8]ARACHCHILLAGE D R,LAFFAN M. Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms[J]. Semin Thromb Hemost,2019,45(6):604-611.
[9]MCMULLIN M F F,MEAD A J,ALI S,et al. A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis:a British society for haematology guideline[J]. Br J Haematol,2019,184(2):161-175.
[10]HASSELBALCH H C,ELVERS M,SCHAFER A I. The pathobiology of thrombosis,microvascular disease,and hemorrhage in the myeloproliferative neoplasms[J]. Blood,2021,137(16):2152-2160.
[11]WEISEL J W,LITVINOV R I. Red blood cells:the forgotten player in hemostasis and thrombosis[J]. J Thromb Haemost,2019,17(2):271-282.
[12]FIDLER T P,XUE C Y,YALCINKAYA M,et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis[J]. Nature,2021,592(7853):296-301.
[13]TEFFERI A,BARBUI T. Polycythemia vera and essential thrombocythemia:2021 update on diagnosis,risk-stratification and management[J]. Am J Hematol,2020,95(12):1599-1613.
[14]ZHU H,JIAN Z H,ZHONG Y,et al. Janus kinase inhibition ameliorates ischemic stroke injury and neuroinflammation through reducing NLRP3 inflammasome activation via JAK2/STAT3 pathway inhibition[J/OL]. Front Immunol,2021,12:714943[2022-10-30]. https://doi.org/10.3389/fimmu.2021.714943.